Free Trial

Evogene Q4 2023 Earnings Report

Evogene logo
$1.24 -0.03 (-2.36%)
(As of 05:26 PM ET)

Evogene EPS Results

Actual EPS
-$1.30
Consensus EPS
-$1.40
Beat/Miss
Beat by +$0.10
One Year Ago EPS
-$0.70

Evogene Revenue Results

Actual Revenue
$0.58 million
Expected Revenue
$1.73 million
Beat/Miss
Missed by -$1.15 million
YoY Revenue Growth
N/A

Evogene Announcement Details

Quarter
Q4 2023
Time
Before Market Opens
Do this Before Elon’s Reveal on January 22nd (Ad)

Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.

I urge you to watch this video now.

Evogene Earnings Headlines

Evogene-Aktie erreicht 52-Wochen-Tief bei 1,25 US-Dollar
Did You See Trump’s Bombshell Exec. Order 001?
Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...
Evogene price target lowered to $5 from $12 at Lake Street
Evogene Ltd. (EVGN) Q3 2024 Earnings Call Transcript
Evogene Reports Third Quarter 2024 Financial Results
See More Evogene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evogene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evogene and other key companies, straight to your email.

About Evogene

Evogene (NASDAQ:EVGN), together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

View Evogene Profile

More Earnings Resources from MarketBeat

Upcoming Earnings